title: Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.
abstract: The global health burden engendered by human immunodeficiency virus (HIV)-induced acquired immunodeficiency syndrome (AIDS) is a sobering reminder of the pressing need for a preventative vaccine. In non-human primate models replicating adenovirus (Ad)-HIV/SIV recombinant vaccine vectors have been shown to stimulate potent immune responses culminating in protection against challenge exposures. Nonetheless, an increase in the transgene carrying capacity of these Ad vectors, currently limited to approximately 3000 base pairs, would greatly enhance their utility. Using a replicating, E3-deleted Ad type 5 host range mutant (Ad5 hr) encoding full-length single-chain HIVBaLgp120 linked to the D1 and D2 domains of rhesus macaque CD4 (rhFLSC) we systematically deleted the genes encoding early region 4 open reading frame 1 (E4orf1) through E4orf4. All the Ad-rhFLSC vectors produced similar levels of viral progeny. Cell cycle analysis of infected human and monkey cells revealed no differences in virus-host interaction. The parental and E4-deleted viruses expressed comparable levels of the transgene with kinetics similar to Ad late proteins. Similar levels of cellular immune responses and transgene-specific antibodies were elicited in vaccinated mice. However, differences in recognition of Ad proteins and induced antibody subtypes were observed, suggesting that the E4 gene products might modulate antibody responses by as yet unknown mechanisms. In short, we have improved the transgene carrying capacity by one thousand base pairs while preserving the replicability, levels of transgene expression, and immunogenicity critical to these vaccine vectors. This additional space allows for flexibility in vaccine design that could not be obtained with the current vector and as such should facilitate the goal of improving vaccine efficacy. To the best of our knowledge, this is the first report describing the effects of these E4 deletions on transgene expression and immunogenicity in a replicating Ad vector.
authors.affiliation: Section on Immune Biology of Retroviral Infection, Vaccine Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Thomas
authors.forename: Rui
authors.initials: R
authors.lastname: Song
authors.forename: Thorsten
authors.initials: T
authors.lastname: Demberg
authors.forename: Diego A
authors.initials: DA
authors.lastname: Vargas-Inchaustegui
authors.forename: David
authors.initials: D
authors.lastname: Venzon
authors.forename: Marjorie
authors.initials: M
authors.lastname: Robert-Guroff
mesh_terms: D000256:Adenoviridae / Q000235:genetics* / Q000276:immunology; D017504:Adenovirus E4 Proteins / Q000235:genetics* / Q000276:immunology; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology; D005260:Female; D015870:Gene Expression; D005822:Genetic Vectors / Q000235:genetics*; D006678:HIV / Q000276:immunology* / Q000502:physiology; D054884:Host-Pathogen Interactions; D051379:Mice; D017384:Sequence Deletion; D013601:T-Lymphocytes / Q000276:immunology; D019076:Transgenes / Q000235:genetics*; D014611:Vaccination; D014765:Viral Vaccines / Q000235:genetics / Q000276:immunology*; D014779:Virus Replication
chemical_list: D017504:Adenovirus E4 Proteins; D000914:Antibodies, Viral; D000956:Antigens, Viral; D014765:Viral Vaccines